skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 
Home » UK Shares » Three Quick Facts » Three Quick Facts: Mitchells & Butlers, Oncimmune and Synairgen

Three things you need to know in the financial markets this morning from investment writer, Tony Cross.

Mitchells & Butlers

Pub and casual dining operator Mitchells & Butlers [LON:MAB] have this morning announced it is seeking to raise a further £350m from shareholders. The new equity is to be offered at a 36% discount to Friday’s closing price and has the support of a group of institutional investors who collectively already own 55% of the business. Between them, this group will fully underwrite the offer, which management see as testament to the fact the business was performing well going into the pandemic.

Subscribe for more stories like this, 8am weekdays - for free!


Oncimmune Holdings

Interim results are out from biotech firm Oncimmune Holdings [LON:ONC] this morning covering the six months to November. Shares have been in focus in recent months as it has made inroads to tackling COVID-19. There’s plenty to cheer shareholders with today’s numbers, showing revenues up six-fold from the same period a year ago, whilst gross profits came in at £1.4m, up from a £50k loss. The board notes that it is delivering against strategic objectives and has created a business with significant revenue potential, with confidence that increasing value can now be delivered to all stakeholders.

Synairgen

Another biotech which was put in the spotlight last summer was Synairgen [LON:SNG]. This morning, they have announced that a US-government funded phase II/III trial has started with patients suffering mild to moderate COVID symptoms but who aren’t yet needing hospitalisation. Management point out that with the risk of mutations making vaccines potentially less effective, there’s still a need for a broad spectrum of treatments to be available.

Sign up for three quick facts and more with our Free Daily Digest newsletter, every weekday morning.

 

This article is not investment advice. Investors should do their own research or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we follow most closely. They represent significant growth stories in our view. Our in-depth reports detail why we like them.

Comments

Subscribe for more stories like this, 8am weekdays - for free!


Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Pepperstone
FP Markets
IG
Spreadex
WisdomTree
ActivTrades
Back To Top